Key facts
- It has raised $22.8M across 2 recorded rounds; the latest was Early Stage VC ($10.0M) in Apr 2026.
- Notable investors include Y Combinator, Alumni Ventures, US National Science Foundation, MassChallenge, National Institutes of Health — 30 tracked in total.
- VenoStent has filed 2 Form Ds with the SEC since 2023, most recently May 2026 ($10.0M sold to 29 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for VenoStent
Funding rounds
2 roundsAbout VenoStent
Developer of a biomedical engineering technology designed to improve the quality and length of life for dialysis patients. The company's technology is made from a new class of shape-memory polymers used primarily as an external stent in coronary artery bypass surgery which requires no sutures, it uses the body's healing mechanisms to mimic the arterial environment in veins, and its net effect is improved AVF usability and durability, and quality and length of life, for chronic kidney disease (CKD) patients, enabling doctors to have a reduction in surgery time, risk of infection, and wound reopening of hemodialysis patients while also reducing failure from vein occlusion.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2015
- Employees
- 35
- Website
- venostent.com/
- Ownership
- Privately Held (backing)
VenoStent doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VenoStent shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VenoStent in its N-PORT filings yet. We sweep new filings monthly.